Most recently, the pan-KRAS inhibitors [173,174] and the pan-RAS inhibitor RMC-7977 [154,155] have been tested in preclinical models, demonstrating the potential to treat various RAS-driven cancers, including PDAC. This evidence concerns the gene KRAS and cancer.